Celltrion is reporting continued growth in prescription rates across Asian markets, with its key biosimilar products achieving leading market share positions. The biopharmaceutical company highlights the increasing adoption of its biosimilars for autoimmune diseases and cancer treatments.
Remsima, Celltrion’s prominent treatment for autoimmune diseases, has established a strong presence in the region. Data from IQVIA, a clinical research provider, shows that as of Q3 2025, Remsima held significant market shares, including 93% in Singapore, 77% in Hong Kong, 73% in Thailand, and 65% in Malaysia. This demonstrates Remsima’s success in penetrating key Asian markets.
Yuflyma, another of Celltrion’s autoimmune therapies, is also gaining popularity in Asia, mirroring the success of Remsima. In Singapore, Yuflyma is now among the top two products in terms of market share and is exceeding the prescription volume of the original reference drug. This signals a growing preference for Celltrion’s biosimilars.
Celltrion is also expanding its footprint in oncology treatments. Herzuma, a biosimilar used in the treatment of breast and gastric cancers, achieved market shares of 87% in Thailand, 57% in Hong Kong, and 51% in Malaysia, as of the third quarter of 2025. This highlights the increasing acceptance of biosimilars in cancer therapy.
Truxima, utilized for treating hematologic cancers, continues to dominate the market. It holds market shares of 90% in Singapore and 79% in Thailand, further solidifying Celltrion’s leading position in the biosimilar market.
Thailand has been a particularly successful market for Celltrion, where collaborations with local university hospitals have been instrumental in expanding its presence. Despite increased competition following the introduction of Thailand’s simplified drug approval system in 2023, Celltrion has maintained its strong market position.
The company is actively working to diversify its product portfolio in the Asian region. Celltrion anticipates securing approval for Stovoclo-Osenveld in Singapore within the current year. Furthermore, the company plans to launch three new products in Thailand: Stekima, Vegzelma, and Omriclor.
“We are continually improving prescription success rates in Asia’s tender-driven markets by leveraging our competitive pricing and stable supply,” stated a Celltrion official. “We plan to launch new products as scheduled and expand our presence in the region, providing broader access to our high-quality biosimilar treatments.”
stlee0329
